CD20×CD3 Bispecific Antibodies in B‐NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research
Open Access
- 5 June 2025
- journal article
- review article
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (6) , e70250
Abstract
Despite advancements in treatment for B‐cell non‐Hodgkin lymphoma (B‐NHL) in recent decades, many patients still relapse or are refractory to treatment, which represents a high unmet medical need. Novel CD20 × CD3 T‐cell–engaging bispecific antibodies (bsAbs) have created a new paradigm for the treatment of B‐NHL. Pivotal studies of four CD20 × CD3 bsAbs, mosunetuzumab, glofitamab, epcoritamab, and odronextamab, as monotherapy, have demonstrated robust responses with generally manageable safety profiles in patients with relapsed or refractory follicular lymphoma and diffuse large B‐cell lymphoma after ≥ 2 lines of systemic therapy. These agents have presented unique challenges (e.g., cytokine release syndrome [CRS]), which have required different strategies to overcome. This review provides a comprehensive overview of the clinical development of these four CD20 × CD3 bsAbs that have been investigated for the treatment of B‐NHL, with a specific focus on translational assessments to select starting doses in first‐in‐human studies, management of CRS, application of modeling and simulation approaches to aid dose escalation and optimization/selection, and strategies used in the design of phase I–III clinical trials. By highlighting learnings and experiences from these four bsAbs assessed, which have not been summarized collectively elsewhere, we aim to promote more efficient study design for novel bsAbs in B‐NHL in the future.Keywords
This publication has 82 references indexed in Scilit:
- Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approachThe Journal of Clinical Pharmacology, 2015
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignanciesScience Translational Medicine, 2015
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood, 2013
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood, 2012
- Role of Interleukin 10 Transcriptional Regulation in Inflammation and Autoimmune DiseaseCritical Reviews in Immunology, 2012
- Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte CultureDrug Metabolism and Disposition, 2011
- Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid ArthritisClinical Pharmacology & Therapeutics, 2011
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI: Journal of the National Cancer Institute, 2009
- Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory responseCurrent Opinion in Pharmacology, 2006